Skip to main content

Table 1 Patient characteristics of measurable lesion type in talimogene laherparepvec study

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

  Any Measurable Lesion Evaluablea Lesion Evaluable for overall lesion- type burdenb
n (%) n (%) n (%)
Any 50 (100) 47 (100) 37 (100)
At least 1 baseline uninjected lesion 48 (96.0) 41 (87.2) 35 (94.6)
Baseline uninjected, non-visceral only 26 (52.0) 23 (48.9) 23 (62.2)
At least 1 visceral lesion at baseline 22 (44.0) 15 (31.9) 12 (32.4)
  1. Denominators are the numbers of patients
  2. aEvaluable indicates at least 2 assessments with valid measurements per investigator
  3. bEvaluable indicates at least 2 visits with non-missing overall lesion-type burden for each respective patient subgroup, or overall tumor burden for “Any”
  4. All patients received at least one dose of talimogene laherparepvec